On the other hand, the second generation inhibitors of mTOR, also called active-site TOR inhibitors (asTORis), were developed for cancer therapy by targeting both TORC1 and TORC2 (Benjamin et al., 2011; Montane and Menand, 2013). Here, CRTC1 is linked to cancer.